Next generation kinase inhibitors
with unique properties

Potent and selective Nanocyclix leads for known

and novel kinases.

 

New partnering opportunity:  Nanocyclix RIPK2 inhibitors

for use in auto-immune diseases

 

READ MORE

Our ambition

Pave the way for a truly personalized approach in cancer.

 

 READ MORE

Translational biomarker approaches
to address patient needs

Pharmaco-imaging in support of therapeutic development

and for drug targeting.

 

 

READ MORE

State-of-the-art models for optimal
predictive value

Patient-derived xenografts and human immune system

models to allow better decisions.

 

 

READ MORE

We partner to advance cancer
research

Creative partnerships to drive development for oncology

and other serious illnesses with no known effective treatment.

 

READ MORE

March 26, 2015
Oncodesign signs preclinical research contract to evaluate antibody-drug conjugates
READ MORE
April 28, 2015
New supportive data for Oncodesign's Nanocyclix based RIPK2 program for auto-immune disease
READ MORE

ONCOLOGY TRANSLATIONAL

EXPERIMENTATION

A large panel of technological and scientific solutions for pharmacological qualification of your compounds : a unique oncology preclinical CRO

DISCOVERY PARTNERING

 

A platform-based approach for the discovery of novel chemical entities with therapeutic and diagnostic potential